Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB)

Barclays PLC cut its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 30.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 120,497 shares of the biopharmaceutical company’s stock after selling 51,700 shares during the quarter. Barclays PLC owned about 0.29% of Cellectar Biosciences worth $258,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Oppenheimer & Co. Inc. acquired a new position in Cellectar Biosciences in the third quarter valued at about $27,000. Sequoia Financial Advisors LLC acquired a new position in shares of Cellectar Biosciences in the 3rd quarter worth approximately $51,000. XTX Topco Ltd lifted its holdings in shares of Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 51,413 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Cellectar Biosciences by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 11,266 shares during the period. Finally, Rosalind Advisors Inc. increased its holdings in Cellectar Biosciences by 35.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock valued at $7,857,000 after purchasing an additional 965,934 shares during the last quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

Cellectar Biosciences Stock Up 0.5 %

Shares of CLRB stock opened at $0.24 on Tuesday. The firm has a 50 day moving average of $0.88 and a two-hundred day moving average of $1.71. The stock has a market capitalization of $10.05 million, a PE ratio of -0.14 and a beta of 1.04. Cellectar Biosciences, Inc. has a 52 week low of $0.22 and a 52 week high of $4.45.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. Analysts expect that Cellectar Biosciences, Inc. will post -1.59 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on CLRB shares. StockNews.com began coverage on Cellectar Biosciences in a research note on Tuesday. They set a “sell” rating on the stock. Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th. Finally, LADENBURG THALM/SH SH assumed coverage on Cellectar Biosciences in a report on Thursday, December 5th. They set a “buy” rating and a $13.00 target price for the company.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.